May 13, 2013
ONO PHARMACEUTICAL CO., LTD. Corporate Communications
TEL: +81-6-6263-5670
Voluntary adoption of International Financial Reporting Standards (IFRS)
Ono Pharmaceutical Co., Ltd. (Chuo-ku, Osaka, President: Gyo Sagara) resolved at the meeting of Board of Directors held today that IFRS is to be adopted to its group's consolidated financial reports and consolidated calculation documents ending on March 31st, 2014. Its financial reports and documents used to be based on Japan Generally Accepted Accounting Principles (Japan GAAP).
Our group has been facilitating business development such as research and development and licensing activities globally in the U.S.A, Europe and Asian regions as well as in Japan. Additionally foreign investors account for about 30 % of the total shareholders as of March 31st,
2013, which has shown large proportion of foreign investors from the past. With these situations considered, we have decided to voluntarily adopt IFRS to disclose financial information based on international standards, improve comparability and enhance convenience of stakeholders
including shareholders, investors and business partners.
Ref:
May 2013
Flash Report and consolidated calculation document ending on
March 31st, 2013
Japan GAAP
June 2013
Annual Report ending on March 31st, 2013
Japan GAAP
Financial information on 1Q to 3Q ending on March 31st, 2014
Japan GAAP
May 2014
Flash Report and consolidated calculation document ending on
March 31st, 2014
IFRS
June 2014
Annual Report ending on March 31st, 2014
IFRS
Consolidated Financial Forecast in Fiscal Year ended March 31, 2014 (FY2013)
under IFRS
Table below shows trial IFRS calculation of the consolidated forecast for the fiscal year ending March 31, 2014, disclosed today.
ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.
ONO PHARMACEUTICAL CO., LTD. 
By 
